TY - JOUR
T1 - Monitoring the safety of a smallpox vaccination program in the United States
T2 - Report of the joint Smallpox Vaccine Safety Working Group of the Advisory Committee on Immunization Practices and the Armed Forces Epidemiological Board
AU - Neff, John
AU - Modlin, John
AU - Birkhead, Guthrie S.
AU - Poland, Gregory
AU - Robertson, Rose Marie
AU - Sepkowitz, Kent
AU - Yancy, Clyde
AU - Gardner, Pierce
AU - Gray, Gregory C.
AU - Maurer, Toby
AU - Siegel, Jane
AU - Guerra, Fernando A.
AU - Berger, Tim
AU - Flanders, W. Dana
AU - Shope, Robert
N1 - Funding Information:
Supplement sponsorship. This article was published as part of a supplement entitled “Posteradication Vaccination against Smallpox,” sponsored by the National Center for Immunization and Respiratory Diseases, Coordinating Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), and by the Coordinating Office for Terrorism Prevention and Emergency Response, CDC.
PY - 2008/3/15
Y1 - 2008/3/15
N2 - In December 2002, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices and the Department of Defense Armed Forces Epidemiological Board formed a joint Smallpox Vaccine Safety Working Group (SVS WG) to provide independent safety oversight for smallpox vaccination safety-monitoring systems. From January 2003 through June 2004, the SVS WG reviewed individual and aggregate safety data on postvaccination adverse events. Serious adverse events were rare because of careful education, prevaccination screening, and strict attention to vaccination-site management. Recent vaccinees safely cared for high-risk patients, adhering to recommended site care. Human immunodeficiency virus-infected individuals without severe immunosuppression had uncomplicated vaccination reactions. Epidemiological studies supported a causal relationship between myocarditis and/or pericarditis and smallpox vaccination. Data supported neutrality regarding hypothesized causal associations between vaccination and dilated cardiomyopathy or ischemic cardiac disease. The SVS WG concurs with recommendations to defer from vaccination any person with ≥3 ischemic cardiac disease risk factors.
AB - In December 2002, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices and the Department of Defense Armed Forces Epidemiological Board formed a joint Smallpox Vaccine Safety Working Group (SVS WG) to provide independent safety oversight for smallpox vaccination safety-monitoring systems. From January 2003 through June 2004, the SVS WG reviewed individual and aggregate safety data on postvaccination adverse events. Serious adverse events were rare because of careful education, prevaccination screening, and strict attention to vaccination-site management. Recent vaccinees safely cared for high-risk patients, adhering to recommended site care. Human immunodeficiency virus-infected individuals without severe immunosuppression had uncomplicated vaccination reactions. Epidemiological studies supported a causal relationship between myocarditis and/or pericarditis and smallpox vaccination. Data supported neutrality regarding hypothesized causal associations between vaccination and dilated cardiomyopathy or ischemic cardiac disease. The SVS WG concurs with recommendations to defer from vaccination any person with ≥3 ischemic cardiac disease risk factors.
UR - http://www.scopus.com/inward/record.url?scp=41649110509&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=41649110509&partnerID=8YFLogxK
U2 - 10.1086/524749
DO - 10.1086/524749
M3 - Article
C2 - 18284367
AN - SCOPUS:41649110509
SN - 1058-4838
VL - 46
SP - S258-S270
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - SUPPL. 3
ER -